The online version of this article (doi:10.1186/s12902-015-0044-z) contains supplementary material, which is available to authorized users.
Funding: This work was funded by a grant to Brigham and Women’s Hospital from Eli Lilly for the MOSAIc study (fund number 2200–107512). The authors retained independent and complete control over the design and implementation of the study, as well as the analyses and writing of the manuscript, the manuscripts contents, and the decision to publish. Eli Lilly reviewed the manuscript, but the final decision to publish and decisions as to what was published were retained by the study authors.
Duality of Interest: Dr. Polinski was an employee at the Division of Pharmacoepidemiology and Pharmacoeconomics when the work was completed and is now an employee of CVS Health. During the time when Dr. Polinski was an employee at the Division of Pharmacoepidemiology and Pharmacoeconomics, she received salary support through her employer for the MOSAIc study. Dr. Kim is supported by the NIH grant K23 AR059677. There are no further disclosures.
Author Contributions: JMP is responsible for the concept and design of the study, the acquisition of data, the analysis and interpretation of data, the drafting the manuscript, and is the guarantor of this work. SCK is responsible for the analysis and interpretation of data, drafting the manuscript, and critical revision of the manuscript. DJ is responsible for the analysis and interpretation of data and critical revision of the manuscript. AH is responsible for analysis and interpretation of data and critical revision of the manuscript. WHS is responsible for analysis and interpretation of data and critical revision of the manuscript. XC is responsible for acquisition of data and critical revision of the manuscript. ER-V is responsible for acquisition of data and critical revision of the manuscript. SS is responsible for concept and design of the study, analysis and interpretation of data, and critical revision of the manuscript. IM is responsible for concept and design of the study, the acquisition of data, the analysis and interpretation of data, and critical revision of the manuscript. JDS is responsible for the concept and design of the study, analysis and interpretation of the data, and critical revision of the manuscript. WE is responsible for analysis and interpretation of data and the drafting the manuscript. GB is responsible for analysis and interpretation of data and critical revision of the manuscript. BHC is responsible for concept and design of the study, the acquisition of data, the analysis and interpretation of data, and critical revision of the manuscript. All authors read and approved the final manuscript.
Among patients with type 2 diabetes, insulin intensification to achieve glycemic targets occurs less often than clinically indicated. Barriers to intensification are not well understood. We present patients’ baseline characteristics from MOSAIc, a study investigating patient-, physician-, and healthcare environment-based factors affecting insulin intensification and subsequent health outcomes.
MOSAIc is a longitudinal, observational study following patients’ diabetes care in 18 countries: United Arab Emirates (UAE), Argentina, Brazil, Canada, China, Germany, India, Israel, Italy, Japan, Mexico, Russia, Saudi Arabia, South Korea, Spain, Turkey, United Kingdom, United States. Eligible patients are age ≥18, have type 2 diabetes, and have used insulin for ≥3 months with/without other antidiabetic medications. Extensive baseline demographic, clinical, and psychosocial data are collected at baseline and regular intervals during the 24-month follow-up. We conducted descriptive analyses of baseline data.
Four thousand three hundred forty one patients met eligibility criteria. Patients received their type 2 diabetes diagnosis 12 ± 8 years prior to baseline visit, yet patients in developing countries were younger than in developed countries (e.g., UAE, 55 ± 10; Germany = 70 ± 10). Saudi Arabians had the highest HbA1c values (9.0 ± 2.2) and Germany (7.5 ± 1.4) among the lowest. Most patients in 5 (28 %) of the 18 countries did not use an oral antidiabetic drug. Over half of patients in fourteen (78 %) countries exclusively used basal insulin; most Indian and Chinese patients exclusively used mixed insulin.
MOSAIc’s baseline data highlight differences in patient characteristics across countries. These patterns, along with physician and healthcare environment differences, may contribute to the likelihood of insulin intensification and subsequent clinical outcomes.
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603–10. PubMed
International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2013. Available from: www.idf.org/diabetesatlas.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia inType2 Diabetes: A Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care. 2012;35:1364–79. CrossRef
World Health Organization. Diabetes Programme 2011 [September 13, 2011]. Available from: http://www.who.int/diabetes/facts/en/.
American Diabetes Association. Economic costs of diabetes in the US in 2007. Diab Care. 2008;31:1–20. CrossRef
Gough S, Frandsen KB, Toft AD. Failure of insulin monotherapy in patients with type II diabetes: a population-based study. Diabet. 2006;55:A114. 447-P. CrossRef
Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diab Care. 2005;28:337–442. CrossRef
Guler S, Vaz JA, Ligthelm R. Intensification lessons with modern premixes: from clinical trial to clinical practice. Diab Res Clin Practice. 2008;81 Suppl 1:S23–30. CrossRef
El-Kebbi IM, Ziemer DC, Musey VC, Gallina DL, Bernard AM, Phillips LS. Diabetes in urban African-Americans. IX. Provider adherence to management protocols. Diab Care. 1997;20(5):698–703. CrossRef
Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diab Care. 2003;28:2673–9. CrossRef
Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. Q J Med. 2000;93:369–74. CrossRef
Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly G, et al. A valuation of patients’ willingness-to-pay for insulin delivery in diabetes. Int J Tech Assess Health Care. 2009;25:359–66. CrossRef
Polinski JM, Curtis BH, Seeger JD, Choudhry NK, Zagar A, Shrank WH. Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study. BMC Endocr Dis. 2012;12:20. CrossRef
International Monetary Fund. World Economic Outlook. 2012.
Polonsky WH, Fischer L, Earles J, Dudl RJ, Lees J, Mullan RA, et al. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diab Care. 2005;28:626–31. CrossRef
VanBuuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–94. CrossRef
World Health Organization. Obesity and overweight 2013 [June 4, 2013]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.
- Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc)
Jennifer M. Polinski
Seoyoung C. Kim
William H. Shrank
John D. Seeger
Bradley H. Curtis
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II